Shares of Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX – Get Free Report) saw an uptick in trading volume on Monday after UBS Group raised their price target on the stock from $21.00 to $22.00. UBS Group currently has a buy rating on the stock. 17,251 shares were traded during mid-day trading, an increase of 41% from the previous session’s volume of 12,207 shares.The stock last traded at $18.60 and had previously closed at $18.24.
Separately, William Blair upgraded shares of Telix Pharmaceuticals Limited American Depositary Shares to a “strong-buy” rating in a report on Tuesday, November 19th.
View Our Latest Report on Telix Pharmaceuticals Limited American Depositary Shares
Telix Pharmaceuticals Limited American Depositary Shares Price Performance
About Telix Pharmaceuticals Limited American Depositary Shares
Telix Pharmaceuticals Limited is a biopharmaceutical company which focused on the development and commercialisation of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It involved in developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases.
Recommended Stories
- Five stocks we like better than Telix Pharmaceuticals Limited American Depositary Shares
- How to Invest in Blue Chip Stocks
- Sizing Up a New Opportunity for NVIDIA Investors
- How to Choose Top Rated Stocks
- Is DeepSeek Challenging NVIDIA’s AI Dominance?
- What is Put Option Volume?
- The 3 Biggest M&A Stock Opportunities for 2025
Receive News & Ratings for Telix Pharmaceuticals Limited American Depositary Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Telix Pharmaceuticals Limited American Depositary Shares and related companies with MarketBeat.com's FREE daily email newsletter.
